Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-03-20
2011-10-11
Shameem, Golam M (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S452000, C548S516000, C514S412000
Reexamination Certificate
active
08034837
ABSTRACT:
The present invention relates to a new crystalline modification of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,S-dihydro-1H-pyrrolizin-S-ylacetic acid which is referred to as polymorph B. It has a peak in the solid state13C-NMR spectrum (with adamantane as external reference standard; CH group d=29.45 ppm) in the range from 179.8 to 180.2 ppm and can be processed directly to a pharmaceutical formulation.
REFERENCES:
patent: 5260451 (1993-11-01), Dannhardt et al.
patent: 5939415 (1999-08-01), Laufer et al.
patent: 5942535 (1999-08-01), Laufer et al.
patent: 5958943 (1999-09-01), Laufer et al.
patent: 7078535 (2006-07-01), Dannhardt et al.
patent: 7132441 (2006-11-01), Gregory et al.
patent: 7595342 (2009-09-01), Hansen et al.
patent: 2002/0028953 (2002-03-01), Kammermeier et al.
patent: 0 397 175 (1990-11-01), None
patent: WO-95/32970 (1995-12-01), None
patent: WO-95/32971 (1995-12-01), None
patent: WO-95/32972 (1995-12-01), None
patent: WO-01/55149 (2001-08-01), None
Cossy et al., “Synthesis of ML-3000, an Inhibitor of Cyclooxygenase and 5-Lipoxygenase”, J.Org.Chem. 1997, 62, 7900-7901.
Cossy et al., “Synthetic Studies Towards ML-3000 A Concise Synthesis of This Non-Steroidal Anti-Inflammatory Drug”, Tetrahedron 1999, 55, 5145-5156.
Curten, Beate, “New Ways for the preparation of substituted pyrrolizines”, Thesis, University Ulm 1998.
Dannhardt et al., “C-5 Functionalized 6,7-Diphenyl-2,3-dihydro-1H-pyrrolizines as Inhibitors of Bovine Cyclooxygenase and 5-Lipoxygenase”, Arch.Pharma. 1994, 327, 509-514.
Kiefer, Werner, “Functionalized 6,7-diary1-2,3-dihydro-1H-pyrrolizines”, Thesis, University of Frankfurt on Main, 1992.
Laufer et al.,“(6,7-Diaryldihydropyrrolizin-5-yl)acetic Acids, a Novel Class of Potent Dual Inhibitors of Both Cyclooxygenase and 5-Liproxygenase”, J.Med.Chem. 1994, 37, 1894-1897.
Rabasseda et al., “Antiinflammatory Cyclooxygenase and 5-Lipoxygenase Inhibitor”, Drugs of the Future 1995, 20(10), 1007-1009.
Dannhardt et al., “Synthesis and Properties of 2,3-Dihydro-1H-pyrrolizines”, Arch.Pharm. 1979, 312, 896-907.
Dannhardt et al., “Antiinflammatory 2,3-Dihydro-1H-pyrrolizines, XIII: Isomeric (Diaryl-dihydropyrroliinyl)acetic Acids and 2-(Diaryldihyropyrrolizinyl)-ethanols”, Arch.Pharm. 1988, 321, 159-162.
Laufer et al., “Synthesis and Evaluation of a Novel Series of Pyrrolizine Derivatives as Dual Cyclooxygenase-1 and 5-Liproxygenase Inhibitors”, Arch.Pharm. Pharm.Med.Chem. 1997, 330, 307-312.
Albrecht Wolfgang
Kammermeier Thomas
Laufer Stefan
Merckle Philipp
Striegel Hans-Gunter
Edwards Angell Palmer & & Dodge LLP
Hsi Jeffrey D.
Merckle GmbH
Russett Mark D.
Shameem Golam M
LandOfFree
Polymorphic form of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphic form of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphic form of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4295266